alzheimer's mri

Summary List Placement

A third member of a Food and Drug Administration expert panel has resigned over the approval of a controversial new Alzheimer’s drug.

In a resignation letter obtained by CNBC, Dr. Aaron Kesselheim, a professor of medicine at Harvard Medical School, said the agency’s decision to approve Biogen’s new Alzheimer’s drug, Aduhelm, “was probably the worst drug approval decision in recent US history.”

Kesselheim joins two other former members of the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee, who resigned from their positions earlier this week, as the backlash against the agency’s accelerated approval process continues to mount.

Aduhelm, formerly known as aducanumab, was approved by the FDA on Monday, despite the prestigious advisory committee voting against the approval of the treatment in November. Though the FDA isn’t required to follow the panel’s recommendation, it typically does so.

The drug has been a point of debate in the scientific community for years, because it failed one of its late-stage clinical trials, and another trial failed to produce conclusive evidence that Aduhelm helped patients with memory and cognition issues. 

But facing ongoing pressure from Alzheimer’s patients’ friends and family, the FDA decided to approve the drug under accelerated approval, a special mechanism that allows authorization on the condition that Biogen runs a follow-up trial to confirm the drug works. The method is usually used for cancer medications, according to CNBC. 

In his resignation letter, Kesselheim said the FDA switched its review to the accelerated pathway “at the last minute” based on a “debatable premise” about the drug’s effectiveness, CNBC reported. He also said it was clear to him that the agency is not “presently capable of adequately integrating the committee’s scientific recommendations into its approval decisions.”

“This will undermine the care of these patients, public trust in the FDA, the pursuit of …read more

Source:: Business Insider


(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *